MedMira Inc (MMIRF) Stock Price, Trades & News

MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.

Financial Strength

Name	Current	Vs Industry
Cash-To-Debt	0.01
Equity-to-Asset	-6.72
Debt-to-Equity	-0.41
Debt-to-EBITDA	-4.61
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	-51.05	Distress Grey Safe
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year EBITDA Growth Rate	-26
	3-Year EPS without NRI Growth Rate	-26
	3-Year FCF Growth Rate	-10.1
	3-Year Book Growth Rate	-21.1

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	99.89
	9-Day RSI	97.4
	14-Day RSI	90.83
	3-1 Month Momentum %	-73.11
	6-1 Month Momentum %	-75.8
	12-1 Month Momentum %	-77.59

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.07
	Quick Ratio	0.06
	Days Inventory	1401.6
	Days Sales Outstanding	2561.57
	Days Payable	19703.36

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-0.2
	Shareholder Yield %	-1.53

Profitability Rank

	Name	Current	Vs Industry		Vs History
	Gross Margin %	70.9
	Operating Margin %	-1287.83
	Net Margin %	-1849.21
	EBITDA Margin %	-1124.34
	FCF Margin %	-1039.71
	OCF Margin %	-1039.71
	ROA %	-92.8
	ROIC %	-14.94
	3-Year ROIIC %	-37.97
	ROC (Joel Greenblatt) %	-116.74
	Moat Score	3
	Tariff Resilience Score	5

GF Value Rank

	Name	Current	Vs Industry		Vs History
	EV-to-EBIT	-22.73
	EV-to-EBITDA	-26.03
	EV-to-Revenue	292.64
	EV-to-FCF	-28.2
	Earnings Yield (Greenblatt) %	-4.4
	FCF Yield %	-4.3

GF Value™

MMIRF

Warning Signs

Warning! GuruFocus detected 6 Severe warning signs with MMIRF. Try a 7-Day Free Trial to check it out.

MedMira Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

MedMira Inc Stock Events

Financials Calendars

	Event	Date	Price ($)
No Event Data

Guru Commentaries on OTCPK:MMIRF

No articles.

Press Release

	Subject	Date
	MedMira Reports Second Quarter Results FY2025	2026-04-01
	MedMira Reports First Quarter Results FY2026	2025-12-30
	MedMira Reports FY2025 Fourth Quarter and Year End Financial Results	2025-11-28
	Health Canada Approves MedMira's Reveal(R) Rapid TP Test - Urgent New Tool In The Battle Against Syphilis	2025-08-26
	MedMira Announces Launch of Clinical Trial for Its Multiplo(R) TP/HIV Self-Test in Canada	2025-07-07
	MedMira Reports Second Quarter Results FY2025	2025-06-30
	MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense	2025-04-17
	MedMira Reports Second Quarter Results FY2025	2025-04-01
	MedMira Announces Partnership with MediGroup Physician Services in the United States	2025-02-27
	MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada	2025-02-25

10/Page

Articles on MedMira Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.